Future Planet Capital

CHAIN Biotechnology Ltd. is a biotechnology company based in London, United Kingdom, that specializes in harnessing Clostridium bacteria for various applications. Founded in 2014, the company focuses on advancing fermentation processes through synthetic biology and automation, particularly utilizing Clostridium strains to produce chiral chemicals. These chemicals are incorporated into a range of products, including nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Notable developments include 3-hydroxybutyrate and (R)-methyl-3HB, a precursor used in glaucoma treatment. CHAIN Biotechnology also aims to create cost-effective fermentation routes from sugar. In addition to its work in fermentation, the company is exploring microbiome therapeutics, developing novel compounds aimed at treating chronic gut-related diseases using its proprietary drug development platform.

HydRegen is a biotechnology company focused on sustainable solutions for chemical manufacturing. It develops bio-based manufacturing technologies and uses biocatalysis to enable the production of clean, safe, and sustainable chemicals. Founded in 2020 and based in Oxford, United Kingdom, the company supports early-stage industrial research and development with greater agility, speed, and predictability. By applying biocatalysis at scale, HydRegen aims to help chemicals and pharmaceutical sectors validate critical cost, productivity, and reproducibility targets, facilitating large-scale deployment of sustainable processes.

HydRegen is a biotechnology company focused on sustainable solutions for chemical manufacturing. It develops bio-based manufacturing technologies and uses biocatalysis to enable the production of clean, safe, and sustainable chemicals. Founded in 2020 and based in Oxford, United Kingdom, the company supports early-stage industrial research and development with greater agility, speed, and predictability. By applying biocatalysis at scale, HydRegen aims to help chemicals and pharmaceutical sectors validate critical cost, productivity, and reproducibility targets, facilitating large-scale deployment of sustainable processes.

Steel Seal manufactures a specialized chemical compound mixture designed to create a hardened seal in damaged areas of head gaskets or blocks. The product reacts under heat and pressure, forming a repair seal for blown steel and aluminum head gaskets, helping customers avoid costly replacements.

Keit Ltd. is a company specializing in the design and manufacture of advanced spectrometers and related instruments, catering to a wide range of applications from ultraviolet to far infrared rays. Incorporated in 2012 and headquartered in Didcot, United Kingdom, Keit is known for its innovative microFTS® design, a Fourier Transform Infrared (FTIR) spectrometer that is notably smaller, lighter, and more rugged than existing systems. Originally developed for space applications, the microFTS® is capable of operating in extreme environments and sets a new standard for real-time liquid-state analyses across various industries, including Pharmaceutical, Chemical, Oil & Gas, and Food & Beverage. Keit's products are also utilized for measuring signal levels, near line vibrations, and analyzing gas or liquid-borne species.

Oxford Advanced Surfaces Group Plc is a company that focuses on surface modification. When it comes to surface modification, we are the experts. As a team we have over 70 years of experience and over 30 patents in this field since our commercialisation out of the University of Oxford. Our team of scientists is highly skilled in the synthesis and formulation of Onto™ materials, so we design and optimise products to meet the needs of real industrial challenges.

CHAIN Biotechnology Ltd. is a biotechnology company based in London, United Kingdom, that specializes in harnessing Clostridium bacteria for various applications. Founded in 2014, the company focuses on advancing fermentation processes through synthetic biology and automation, particularly utilizing Clostridium strains to produce chiral chemicals. These chemicals are incorporated into a range of products, including nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Notable developments include 3-hydroxybutyrate and (R)-methyl-3HB, a precursor used in glaucoma treatment. CHAIN Biotechnology also aims to create cost-effective fermentation routes from sugar. In addition to its work in fermentation, the company is exploring microbiome therapeutics, developing novel compounds aimed at treating chronic gut-related diseases using its proprietary drug development platform.

CHAIN Biotechnology Ltd. is a biotechnology company based in London, United Kingdom, that specializes in harnessing Clostridium bacteria for various applications. Founded in 2014, the company focuses on advancing fermentation processes through synthetic biology and automation, particularly utilizing Clostridium strains to produce chiral chemicals. These chemicals are incorporated into a range of products, including nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Notable developments include 3-hydroxybutyrate and (R)-methyl-3HB, a precursor used in glaucoma treatment. CHAIN Biotechnology also aims to create cost-effective fermentation routes from sugar. In addition to its work in fermentation, the company is exploring microbiome therapeutics, developing novel compounds aimed at treating chronic gut-related diseases using its proprietary drug development platform.

Oxford Advanced Surfaces Group Plc is a company that focuses on surface modification. When it comes to surface modification, we are the experts. As a team we have over 70 years of experience and over 30 patents in this field since our commercialisation out of the University of Oxford. Our team of scientists is highly skilled in the synthesis and formulation of Onto™ materials, so we design and optimise products to meet the needs of real industrial challenges.

CHAIN Biotechnology Ltd. is a biotechnology company based in London, United Kingdom, that specializes in harnessing Clostridium bacteria for various applications. Founded in 2014, the company focuses on advancing fermentation processes through synthetic biology and automation, particularly utilizing Clostridium strains to produce chiral chemicals. These chemicals are incorporated into a range of products, including nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Notable developments include 3-hydroxybutyrate and (R)-methyl-3HB, a precursor used in glaucoma treatment. CHAIN Biotechnology also aims to create cost-effective fermentation routes from sugar. In addition to its work in fermentation, the company is exploring microbiome therapeutics, developing novel compounds aimed at treating chronic gut-related diseases using its proprietary drug development platform.

ZuvaSyntha Limited is an industrial biotechnology company based in Welwyn Garden City, United Kingdom, founded in 2011. The company specializes in developing innovative bio-routes for the production of renewable chemicals from C1 feedstocks. ZuvaSyntha offers a range of contract research and development services, including product and process development, metabolite synthesis, biocatalysis, metabolic pathway engineering, and fermentation. Initially incorporated as BioSyntha Technology Ltd., the company rebranded to ZuvaSyntha Limited in May 2015 and currently operates as a subsidiary of ZuvaChem, Inc.

Keit Ltd. is a company specializing in the design and manufacture of advanced spectrometers and related instruments, catering to a wide range of applications from ultraviolet to far infrared rays. Incorporated in 2012 and headquartered in Didcot, United Kingdom, Keit is known for its innovative microFTS® design, a Fourier Transform Infrared (FTIR) spectrometer that is notably smaller, lighter, and more rugged than existing systems. Originally developed for space applications, the microFTS® is capable of operating in extreme environments and sets a new standard for real-time liquid-state analyses across various industries, including Pharmaceutical, Chemical, Oil & Gas, and Food & Beverage. Keit's products are also utilized for measuring signal levels, near line vibrations, and analyzing gas or liquid-borne species.

ZuvaSyntha Limited is an industrial biotechnology company based in Welwyn Garden City, United Kingdom, founded in 2011. The company specializes in developing innovative bio-routes for the production of renewable chemicals from C1 feedstocks. ZuvaSyntha offers a range of contract research and development services, including product and process development, metabolite synthesis, biocatalysis, metabolic pathway engineering, and fermentation. Initially incorporated as BioSyntha Technology Ltd., the company rebranded to ZuvaSyntha Limited in May 2015 and currently operates as a subsidiary of ZuvaChem, Inc.

ZuvaSyntha Limited is an industrial biotechnology company based in Welwyn Garden City, United Kingdom, founded in 2011. The company specializes in developing innovative bio-routes for the production of renewable chemicals from C1 feedstocks. ZuvaSyntha offers a range of contract research and development services, including product and process development, metabolite synthesis, biocatalysis, metabolic pathway engineering, and fermentation. Initially incorporated as BioSyntha Technology Ltd., the company rebranded to ZuvaSyntha Limited in May 2015 and currently operates as a subsidiary of ZuvaChem, Inc.

CHAIN Biotechnology Ltd. is a biotechnology company based in London, United Kingdom, that specializes in harnessing Clostridium bacteria for various applications. Founded in 2014, the company focuses on advancing fermentation processes through synthetic biology and automation, particularly utilizing Clostridium strains to produce chiral chemicals. These chemicals are incorporated into a range of products, including nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Notable developments include 3-hydroxybutyrate and (R)-methyl-3HB, a precursor used in glaucoma treatment. CHAIN Biotechnology also aims to create cost-effective fermentation routes from sugar. In addition to its work in fermentation, the company is exploring microbiome therapeutics, developing novel compounds aimed at treating chronic gut-related diseases using its proprietary drug development platform.

ZuvaSyntha Limited is an industrial biotechnology company based in Welwyn Garden City, United Kingdom, founded in 2011. The company specializes in developing innovative bio-routes for the production of renewable chemicals from C1 feedstocks. ZuvaSyntha offers a range of contract research and development services, including product and process development, metabolite synthesis, biocatalysis, metabolic pathway engineering, and fermentation. Initially incorporated as BioSyntha Technology Ltd., the company rebranded to ZuvaSyntha Limited in May 2015 and currently operates as a subsidiary of ZuvaChem, Inc.

Keit Ltd. is a company specializing in the design and manufacture of advanced spectrometers and related instruments, catering to a wide range of applications from ultraviolet to far infrared rays. Incorporated in 2012 and headquartered in Didcot, United Kingdom, Keit is known for its innovative microFTS® design, a Fourier Transform Infrared (FTIR) spectrometer that is notably smaller, lighter, and more rugged than existing systems. Originally developed for space applications, the microFTS® is capable of operating in extreme environments and sets a new standard for real-time liquid-state analyses across various industries, including Pharmaceutical, Chemical, Oil & Gas, and Food & Beverage. Keit's products are also utilized for measuring signal levels, near line vibrations, and analyzing gas or liquid-borne species.

ZuvaSyntha Limited is an industrial biotechnology company based in Welwyn Garden City, United Kingdom, founded in 2011. The company specializes in developing innovative bio-routes for the production of renewable chemicals from C1 feedstocks. ZuvaSyntha offers a range of contract research and development services, including product and process development, metabolite synthesis, biocatalysis, metabolic pathway engineering, and fermentation. Initially incorporated as BioSyntha Technology Ltd., the company rebranded to ZuvaSyntha Limited in May 2015 and currently operates as a subsidiary of ZuvaChem, Inc.

Agilent Raman Spectroscopy’s proprietary technologies use novel variants of Raman spectroscopy. Their instruments can rapidly and accurately identify materials hidden inside objects or through opaque barriers such as plastic, coloured glass, paper and skin, or can measure the concentrations of materials in mixtures, with a high degree of accuracy. Agilent Raman Spectroscopy is formerly known as Cobalt Light Systems and is part of Agilent.

Agilent Raman Spectroscopy’s proprietary technologies use novel variants of Raman spectroscopy. Their instruments can rapidly and accurately identify materials hidden inside objects or through opaque barriers such as plastic, coloured glass, paper and skin, or can measure the concentrations of materials in mixtures, with a high degree of accuracy. Agilent Raman Spectroscopy is formerly known as Cobalt Light Systems and is part of Agilent.

Agilent Raman Spectroscopy’s proprietary technologies use novel variants of Raman spectroscopy. Their instruments can rapidly and accurately identify materials hidden inside objects or through opaque barriers such as plastic, coloured glass, paper and skin, or can measure the concentrations of materials in mixtures, with a high degree of accuracy. Agilent Raman Spectroscopy is formerly known as Cobalt Light Systems and is part of Agilent.

Chameleon BioSurfaces specializes in innovative surface design technology for the medical device industry. The company collaborates closely with its clients to create tailored solutions that address specific challenges and opportunities related to medical devices and implants. Utilizing a patented electrodeposition process, Chameleon applies specialized coatings directly onto metal surfaces, allowing for customization based on clinical needs. This approach enables the development of advanced medical devices that meet stringent performance and safety standards.